A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (RESILIENT)
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Mary A Kelley, MPH
- Phone Number: 619-395-5767
- Email: mary.kelley@tonixpharma.com
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85012
- Tonix Clinical Site
-
-
California
-
Oceanside, California, United States, 92056
- Tonix Clinical Site
-
Santa Ana, California, United States, 92705
- Tonix Clinical Site
-
Temecula, California, United States, 92591
- Tonix Clinical Site
-
-
Connecticut
-
Cromwell, Connecticut, United States, 06416
- Tonix Clinical Site
-
-
Florida
-
Fort Myers, Florida, United States, 33912
- Tonix Clinical Site
-
Jacksonville, Florida, United States, 32256
- Tonix Clinical Site
-
Miami Lakes, Florida, United States, 33016
- Tonix Clinical Site
-
Ocala, Florida, United States, 34470
- Tonix Clinical Site
-
Oldsmar, Florida, United States, 34677
- Tonix Clinical Site
-
Orlando, Florida, United States, 32801
- Tonix Clinical Site
-
-
Georgia
-
Alpharetta, Georgia, United States, 30022
- Tonix Clinical Site
-
Atlanta, Georgia, United States, 30329
- Tonix Clinical Site
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- Tonix Clinical Site
-
-
Iowa
-
West Des Moines, Iowa, United States, 50265
- Tonix Clinical Site
-
-
Kansas
-
Prairie Village, Kansas, United States, 66208
- Tonix Clinical Site
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
- Tonix Clinical Site
-
New Orleans, Louisiana, United States, 70115
- Tonix Clinical Site
-
Prairieville, Louisiana, United States, 70769
- Tonix Clinical Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02131
- Tonix Clinical Site
-
-
Mississippi
-
Gulfport, Mississippi, United States, 39501
- Tonix Clinical Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Tonix Clinical Site
-
-
New York
-
Williamsville, New York, United States, 14221
- Tonix Clinical Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Tonix Clinical Site
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74133
- Tonix Clinical Site
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Tonix Clinical Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29407
- Tonix Clinical Site
-
-
Texas
-
Austin, Texas, United States, 78737
- Tonix Clinical Site
-
Dallas, Texas, United States, 75231
- Tonix Clinical Site
-
McKinney, Texas, United States, 75070
- Tonix Clinical Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22911
- Tonix Clinical Site
-
Danville, Virginia, United States, 24541
- Tonix Clinical Site
-
-
Wisconsin
-
Kenosha, Wisconsin, United States, 53144
- Tonix Clinical Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient is male or female 18 to 65 years of age, inclusive.
- The patient has a diagnosis of primary FM as defined by the 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria (American College of Rheumatology Preliminary Diagnostic Criteria)
Exclusion Criteria:
- The patient has been diagnosed with infectious or inflammatory arthritis (e.g., rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis), systemic lupus erythematosus, untreated or active gout (ie, any acute attacks within past 2 years is exclusionary), or meets criteria for other type of systemic autoimmune disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo SL Tablet
1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
|
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks.
At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Other Names:
|
|
Experimental: TNX-102 SL Tablet, 5.6 mg
1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks, then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
|
Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks.
At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores.
Time Frame: Baseline (Day -7 to Day -1), Week 14
|
Change from Baseline to the Week 14 endpoint in the diary Numerical Rating Scale (NRS) weekly average of daily self-reported average pain severity scores.
Scores range from 0 to 10 where a higher score means worse outcome.
|
Baseline (Day -7 to Day -1), Week 14
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Patients With a Patient's Global Impression of Change (PGIC) Rating of "Very Much Improved" or "Much Improved" at the Week 14 Endpoint
Time Frame: Week 14
|
The PGIC is a fibromyalgia specific validated instrument on a scale of 1 to 7, where a score of 1 indicates the highest level of improvement and a score of 7 indicates a much worse outcome.
|
Week 14
|
|
Change From Baseline in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score at the Week 14 Endpoint
Time Frame: Day 1, Week 14
|
Change from Baseline in the FIQ-R Symptoms domain score at the Week 14 endpoint.
Scores on the symptoms domain range from 0 to 90 where a higher score means worse outcome.
|
Day 1, Week 14
|
|
Change From Baseline in the FIQ-R Function Domain Score at the Week 14 Endpoint
Time Frame: Day 1, Week 14
|
The FIQ-R is a validated questionnaire.
Scores on the function domain range from 0 to 90 where a higher score means worse outcome.
|
Day 1, Week 14
|
|
Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance at the Week 14 Endpoint
Time Frame: Day 1, Week 14
|
The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome.
The total score is reported on a range of 8 to 40.
Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.
|
Day 1, Week 14
|
|
Change From Baseline in the PROMIS Score for Fatigue at the Week 14 Endpoint
Time Frame: Day 1, Week 14
|
The PROMIS fatigue short form 8a consists of 8 questions on a 5 point scale (1 to 5) where a higher score indicates a worse outcome.
The total score is reported on a range of 8 to 40.
Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.
|
Day 1, Week 14
|
|
Change From Baseline in the Weekly Average of the Daily Diary Assessment of Sleep Quality at the Week 14 Endpoint
Time Frame: Baseline (Day -7 to Day -1), Week 14
|
Patients provide a daily numeric assessment of their sleep quality for the previous night, via an electronic diary, using an 11-point NRS.
Scores range from 0 (best possible sleep) to 10 (worst possible sleep).
|
Baseline (Day -7 to Day -1), Week 14
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Gregory Sullivan, MD, Tonix Pharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Musculoskeletal Diseases
- Nervous System Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Rheumatic Diseases
- Fibromyalgia
- Myofascial Pain Syndromes
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Neuromuscular Agents
- Muscle Relaxants, Central
- Antidepressive Agents, Tricyclic
- Cyclobenzaprine
Other Study ID Numbers
Other Study ID Numbers
- TNX-CY-F307
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.